Document is current
Any future updates will be listed below
-
Authors
Haitsma Mulier, Jelle L. G.
Verbeek, Ellen
Martin, Florian P.
Poulain, Cécile
Motos, Ana
Schweitzer, Valentijn A.
Bonten, Marc J. M.
de Grooth, Harm-Jan
Torres, Antoni
Roquilly, Antoine
Derde, Lennie P. G.
Cremer, Olaf L.
- License Information
-
More Information
Article History
Received: 28 May 2026
Accepted: 1 September 2026
First Online: 22 September 2026
Declarations
Ethical approval and consent to participate: MARS was approved by the local institutional review board (METC NedMec ref. 10-056C). A compliance review (ref. 23U-0103) determined that the current analysis was not subject to the Dutch Medical Research Involving Human Subjects Act. Data were used under the no-objection policy of the General Data Protection Regulation. ATLANREA was approved by the French ethics committee (ref. IRB 00010254–2020-041), and all participants consented to the use of their data.
Consent for publication: Not applicable.
Competing interests: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. M.B. is a member of the advisory boards of Merck, GSK, and Jansen Vaccines and reports payments to his institution from Merck, GSK, Sequiris, TechnoPhage, Attea Pharma, Phaxiam, Janssen Vaccines, Pfizer and Sanofi. A.T. declares consulting fees from Pfizer, Poliphor, MSD, Jansen and OM Pharma. All other authors report no potential conflicts related to the work reported in this manuscript.
